Matches in SemOpenAlex for { <https://semopenalex.org/work/W1891778267> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W1891778267 abstract "Adult T-cell leukemia lymphoma (ATLL) acute and lymphoma subtypes have a poor prognosis, with median survival of about one year. The malignant cells are characterized by high levels of nuclear factor kappa B (NFkappaB). In order to improve therapy, we assessed the safety, tolerance, and efficacy of a combination of dose-adjusted EPOCH chemotherapy (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin), combined with proteasome inhibitor, bortezomib, to prevent degradation of the inhibitor of NFkappaB (IkappaB). In addition, integrase inhibitor, raltegravir, was added to the regimen to block virus replication occurring during treatment. This multicenter study enrolled 18 of 20 planned subjects over 2.5 yrs in the U.S., although 15 of the subjects were born in the Caribbean. Six subjects had acute ATLL, and the remainder lymphoma subtype, all but one with stage 4 disease. Therapy was well tolerated; subjects received 1-6 cycles of therapy (mean 4.5 cycles). Two subjects achieved complete remission lasting for >12 mos, 10 subjects had a partial remission, and 3 subjects had stable disease as their best response. Baseline calcium level, absolute lymphocyte count, and proviral DNA load were not predictive of response. Correlations with proviral expression, integration site, and integrase gene analyses will be presented. Supported by NIH grants CA94056, CA1730, CA63413, Lymphoma Leukemia Society grant 6067-10, and Lymphoma Research Foundation grant 307181203. Authors’ details Division of Oncology, Washington University, St Louis, MO, USA. University of Miami, Miami, FL, USA. Lymphoma & Hematology Division, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Divisions of Hematology-Oncology, Montefiore Hospital, New York, NY, USA. Columbia University, New York, NY, USA. Division of Hematologic Malignancies, Johns Hopkins University, Baltimore, MD, USA. NINDS, NIH, Bethesda, MD, USA." @default.
- W1891778267 created "2016-06-24" @default.
- W1891778267 creator A5014543424 @default.
- W1891778267 creator A5014958059 @default.
- W1891778267 creator A5019666650 @default.
- W1891778267 creator A5033571971 @default.
- W1891778267 creator A5043634316 @default.
- W1891778267 creator A5049077444 @default.
- W1891778267 creator A5049384875 @default.
- W1891778267 creator A5051578610 @default.
- W1891778267 creator A5054621006 @default.
- W1891778267 creator A5068289010 @default.
- W1891778267 creator A5068593672 @default.
- W1891778267 creator A5069227190 @default.
- W1891778267 creator A5073569034 @default.
- W1891778267 date "2015-08-28" @default.
- W1891778267 modified "2023-10-07" @default.
- W1891778267 title "Phase I / II trial of dose adjusted EPOCH chemotherapy with bortezomib combined with integrase inhibitor therapy for HTLV-1 associated T-cell leukemia lymphoma" @default.
- W1891778267 doi "https://doi.org/10.1186/1742-4690-12-s1-p21" @default.
- W1891778267 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4578736" @default.
- W1891778267 hasPublicationYear "2015" @default.
- W1891778267 type Work @default.
- W1891778267 sameAs 1891778267 @default.
- W1891778267 citedByCount "0" @default.
- W1891778267 crossrefType "journal-article" @default.
- W1891778267 hasAuthorship W1891778267A5014543424 @default.
- W1891778267 hasAuthorship W1891778267A5014958059 @default.
- W1891778267 hasAuthorship W1891778267A5019666650 @default.
- W1891778267 hasAuthorship W1891778267A5033571971 @default.
- W1891778267 hasAuthorship W1891778267A5043634316 @default.
- W1891778267 hasAuthorship W1891778267A5049077444 @default.
- W1891778267 hasAuthorship W1891778267A5049384875 @default.
- W1891778267 hasAuthorship W1891778267A5051578610 @default.
- W1891778267 hasAuthorship W1891778267A5054621006 @default.
- W1891778267 hasAuthorship W1891778267A5068289010 @default.
- W1891778267 hasAuthorship W1891778267A5068593672 @default.
- W1891778267 hasAuthorship W1891778267A5069227190 @default.
- W1891778267 hasAuthorship W1891778267A5073569034 @default.
- W1891778267 hasBestOaLocation W18917782671 @default.
- W1891778267 hasConcept C121332964 @default.
- W1891778267 hasConcept C126322002 @default.
- W1891778267 hasConcept C1276947 @default.
- W1891778267 hasConcept C142462285 @default.
- W1891778267 hasConcept C143998085 @default.
- W1891778267 hasConcept C150846664 @default.
- W1891778267 hasConcept C159047783 @default.
- W1891778267 hasConcept C2776364478 @default.
- W1891778267 hasConcept C2776694085 @default.
- W1891778267 hasConcept C2777302000 @default.
- W1891778267 hasConcept C2777478702 @default.
- W1891778267 hasConcept C2778461978 @default.
- W1891778267 hasConcept C2779338263 @default.
- W1891778267 hasConcept C2780317896 @default.
- W1891778267 hasConcept C2993143319 @default.
- W1891778267 hasConcept C3013748606 @default.
- W1891778267 hasConcept C502942594 @default.
- W1891778267 hasConcept C71924100 @default.
- W1891778267 hasConceptScore W1891778267C121332964 @default.
- W1891778267 hasConceptScore W1891778267C126322002 @default.
- W1891778267 hasConceptScore W1891778267C1276947 @default.
- W1891778267 hasConceptScore W1891778267C142462285 @default.
- W1891778267 hasConceptScore W1891778267C143998085 @default.
- W1891778267 hasConceptScore W1891778267C150846664 @default.
- W1891778267 hasConceptScore W1891778267C159047783 @default.
- W1891778267 hasConceptScore W1891778267C2776364478 @default.
- W1891778267 hasConceptScore W1891778267C2776694085 @default.
- W1891778267 hasConceptScore W1891778267C2777302000 @default.
- W1891778267 hasConceptScore W1891778267C2777478702 @default.
- W1891778267 hasConceptScore W1891778267C2778461978 @default.
- W1891778267 hasConceptScore W1891778267C2779338263 @default.
- W1891778267 hasConceptScore W1891778267C2780317896 @default.
- W1891778267 hasConceptScore W1891778267C2993143319 @default.
- W1891778267 hasConceptScore W1891778267C3013748606 @default.
- W1891778267 hasConceptScore W1891778267C502942594 @default.
- W1891778267 hasConceptScore W1891778267C71924100 @default.
- W1891778267 hasIssue "S1" @default.
- W1891778267 hasLocation W18917782671 @default.
- W1891778267 hasLocation W18917782672 @default.
- W1891778267 hasLocation W18917782673 @default.
- W1891778267 hasOpenAccess W1891778267 @default.
- W1891778267 hasPrimaryLocation W18917782671 @default.
- W1891778267 hasRelatedWork W1715045834 @default.
- W1891778267 hasRelatedWork W2149644652 @default.
- W1891778267 hasRelatedWork W2213486556 @default.
- W1891778267 hasRelatedWork W2311305025 @default.
- W1891778267 hasRelatedWork W2366439715 @default.
- W1891778267 hasRelatedWork W2370145755 @default.
- W1891778267 hasRelatedWork W2371666691 @default.
- W1891778267 hasRelatedWork W2378355431 @default.
- W1891778267 hasRelatedWork W2406230970 @default.
- W1891778267 hasRelatedWork W2023169394 @default.
- W1891778267 hasVolume "12" @default.
- W1891778267 isParatext "false" @default.
- W1891778267 isRetracted "false" @default.
- W1891778267 magId "1891778267" @default.
- W1891778267 workType "article" @default.